Astellas Sued Over Efforts To Block Generic Prograf

Law360, New York (March 1, 2011, 11:44 PM EST) -- The owners of a retail drug chain filed an antitrust class action Tuesday accusing Astellas Pharma US Inc. of abusing the U.S. Food and Drug Administration’s drug approval process to delay a generic version of Prograf and corner the market for the immunosuppressant.

Stephen L. LaFrance Holdings Inc. filed a complaint in the U.S. District Court for the District of Massachusetts claiming Astellas violated the Sherman Act by illegally maintaining a monopoly in the market for Prograf and charging supracompetitive prices for the drug.

The Pine...
To view the full article, register now.




Case Information

Case Title

Stephen L. LaFrance Holdings, Inc. et al v. Astellas Pharma US, Inc.

Case Number




Nature of Suit



Rya W. Zobel

Date Filed

February 28, 2011

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.